KLUS Pharma is the wholly-owned U.S. subsidiary of Kelun-Biotech, based in Cranbury, NJ. Kelun-Biotech is based in Chengdu, China.
We strive to discover and develop innovative biologics for the treatment of cancer and other serious diseases, addressing unmet needs and creating affordable medicines.
We have a rich pipeline of antibody-based therapeutics targeting solid tumors and clotting disorders, with multiple ongoing clinical trials.
Our antibodies undergo affinity maturation, humanization, and Fc engineering, generating lead candidates with optimal efficacy and safety.
Our platform supports a wide variety of bispecific designs which allows for flexibility in selecting the optimal design based on intended MOA.
Our third-generation ADC platform allows for site-specific conjugation of potent warheads to antibodies, with a variety of linkers and tunable DAR.
Mar 26, 2021
Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. and UK company Ellipses Pharma Ltd. Announce a Licensing Agreement for Innovative Small Molecule Cancer Therapeutics
Mar 5, 2021
KLUS Pharma will attend BIO-Europe Spring Digital Event held on March 22-25, 2021.
Sep 2, 2020
The IND for KL-A289, an anti-LAG-3 monoclonal antibody, was recently approved by the NMPA in China.